UA118380C2 - Заміщені сполуки дигідроізохінолінону - Google Patents

Заміщені сполуки дигідроізохінолінону

Info

Publication number
UA118380C2
UA118380C2 UAA201611695A UAA201611695A UA118380C2 UA 118380 C2 UA118380 C2 UA 118380C2 UA A201611695 A UAA201611695 A UA A201611695A UA A201611695 A UAA201611695 A UA A201611695A UA 118380 C2 UA118380 C2 UA 118380C2
Authority
UA
Ukraine
Prior art keywords
compounds
substituted
substituted dihydroisoquinolinone
dihydroisoquinolinone compounds
salts
Prior art date
Application number
UAA201611695A
Other languages
English (en)
Inventor
Майкл Реймонд Коллінз
Роберт Стівен Кан'я
Роберт Арнолд Кампф
Пай-Пай Канґ
Даніел Тайлер Ріктер
Скотт Ченнінґ Саттон
Мартін Джеймс Вайтс
Original Assignee
Пфайзер Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Інк. filed Critical Пфайзер Інк.
Publication of UA118380C2 publication Critical patent/UA118380C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

Даний винахід стосується сполук загальної формули (І) EMBED ISISServer , (I) в якій R1, R2, R3, R4, L, X та Z є такими, як визначено в даному документі, та їх фармацевтично прийнятних солей, фармацевтичних композицій, що містять такі сполуки та солі, та способів застосування таких сполук, солей та композицій для лікування ненормального клітинного росту, включаючи захворювання на рак.
UAA201611695A 2014-06-17 2015-06-05 Заміщені сполуки дигідроізохінолінону UA118380C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462013410P 2014-06-17 2014-06-17
US201562156533P 2015-05-04 2015-05-04
PCT/IB2015/054272 WO2015193765A1 (en) 2014-06-17 2015-06-05 Substituted dihydroisoquinolinone compounds

Publications (1)

Publication Number Publication Date
UA118380C2 true UA118380C2 (uk) 2019-01-10

Family

ID=53434412

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201611695A UA118380C2 (uk) 2014-06-17 2015-06-05 Заміщені сполуки дигідроізохінолінону

Country Status (40)

Country Link
US (4) US9481666B2 (uk)
EP (2) EP3157915B1 (uk)
JP (1) JP6152495B1 (uk)
KR (1) KR101877187B1 (uk)
CN (1) CN107207464B (uk)
AP (1) AP2016009605A0 (uk)
AU (1) AU2015275826B2 (uk)
BR (1) BR112016029612B1 (uk)
CA (1) CA2894298C (uk)
CL (1) CL2016003246A1 (uk)
CR (2) CR20160574A (uk)
CU (1) CU24408B1 (uk)
CY (1) CY1121706T1 (uk)
DK (1) DK3157915T3 (uk)
EA (1) EA031892B1 (uk)
ES (1) ES2721031T3 (uk)
GE (1) GEP20186933B (uk)
HR (1) HRP20190604T1 (uk)
HU (1) HUE042964T2 (uk)
IL (1) IL248991B (uk)
LT (1) LT3157915T (uk)
MA (1) MA40225B1 (uk)
MD (1) MD4820C1 (uk)
ME (1) ME03419B (uk)
MX (1) MX2016016764A (uk)
MY (1) MY185765A (uk)
NZ (1) NZ726108A (uk)
PE (1) PE20161552A1 (uk)
PH (1) PH12016502378A1 (uk)
PL (1) PL3157915T3 (uk)
PT (1) PT3157915T (uk)
RS (1) RS58632B1 (uk)
SG (1) SG11201609386YA (uk)
SI (1) SI3157915T1 (uk)
SV (1) SV2016005333A (uk)
TN (1) TN2016000529A1 (uk)
TW (1) TWI561516B (uk)
UA (1) UA118380C2 (uk)
UY (1) UY36170A (uk)
WO (1) WO2015193765A1 (uk)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
KR101877187B1 (ko) 2014-06-17 2018-07-10 화이자 인코포레이티드 치환된 다이하이드로이소퀴놀린온 화합물
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
ES2801423T3 (es) 2016-05-05 2021-01-11 Glaxosmithkline Ip No 2 Ltd Potenciador de inhibidores del homólogo Zeste 2
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2019016112A1 (en) 2017-07-17 2019-01-24 AbbVie Deutschland GmbH & Co. KG SUBSTITUTED QUINOLINE COMPOUNDS IN POSITIONS 1, 2, 3 AND 4 AS MODULATORS OF S1P
AU2018369841A1 (en) * 2017-11-14 2020-05-07 Pfizer Inc. EZH2 inhibitor combination therapies
AU2019214861B2 (en) 2018-01-31 2021-11-18 Mirati Therapeutics, Inc. PRC2 inhibitors
CN111989325A (zh) 2018-04-18 2020-11-24 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
US20230012362A1 (en) * 2018-10-24 2023-01-12 Vanderbilt University Wdr5 inhibitors and modulators
KR20200101219A (ko) * 2019-02-19 2020-08-27 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
WO2022018594A1 (en) 2020-07-20 2022-01-27 Pfizer Inc. Synthesis of novel intermediates for substituted 3,4-dihydroisoquinolinones
US20240101535A1 (en) * 2020-12-11 2024-03-28 Etern Biopharma (Shanghai) Co., Ltd. Dihydroisoquinolinone derivative and application thereof
WO2023098880A1 (zh) * 2021-12-02 2023-06-08 上海翰森生物医药科技有限公司 稠环类衍生物调节剂、其制备方法和应用
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007022280A1 (en) 2005-08-16 2007-02-22 Memory Pharmaceuticals Corporation Phosphodiesterase 10 inhibitors
CA2631777A1 (en) * 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
CN102124000B (zh) * 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
EP2566479B1 (en) 2010-05-07 2014-12-24 GlaxoSmithKline LLC Azaindazoles
ES2534804T3 (es) 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
NZ603454A (en) 2010-05-07 2014-06-27 Glaxosmithkline Llc Indoles useful for treating cellular proliferation diseases such as cancer
ES2570380T3 (es) 2010-09-10 2016-05-18 Epizyme Inc Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
TWI598336B (zh) * 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
AU2012315566A1 (en) 2011-09-30 2014-04-17 Glaxosmithkline Llc Methods of treating cancer
WO2013059944A1 (en) * 2011-10-28 2013-05-02 British Columbia Cancer Agency Branch Epigenetic regulators and uses thereof
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US20150239842A1 (en) 2012-09-28 2015-08-27 Pfizer Inc. Benzamide and heterobenzamide compounds
SG11201504754QA (en) 2012-12-21 2015-07-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MY191741A (en) 2012-12-21 2022-07-13 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
RS57690B1 (sr) 2012-12-21 2018-11-30 Hoffmann La Roche Peptidi kao agonisti oksitocina
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
UA116553C2 (uk) 2012-12-21 2018-04-10 Санофі Пептидна сполука - агоніст рецептора glp-1 i glp
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
CA2894542C (en) 2012-12-21 2023-10-31 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR101877187B1 (ko) 2014-06-17 2018-07-10 화이자 인코포레이티드 치환된 다이하이드로이소퀴놀린온 화합물

Also Published As

Publication number Publication date
LT3157915T (lt) 2019-04-25
WO2015193765A1 (en) 2015-12-23
BR112016029612B1 (pt) 2021-01-19
CN107207464B (zh) 2019-10-22
US20190040047A1 (en) 2019-02-07
US10570121B2 (en) 2020-02-25
CA2894298A1 (en) 2015-12-17
HRP20190604T1 (hr) 2019-05-31
KR20170016493A (ko) 2017-02-13
MX2016016764A (es) 2017-04-25
ME03419B (me) 2020-01-20
MY185765A (en) 2021-06-06
PT3157915T (pt) 2019-05-16
EA031892B1 (ru) 2019-03-29
MD20160136A2 (ro) 2017-05-31
JP2017519013A (ja) 2017-07-13
AU2015275826B2 (en) 2019-05-16
CY1121706T1 (el) 2020-07-31
IL248991A0 (en) 2017-01-31
EP3521285A1 (en) 2019-08-07
RS58632B1 (sr) 2019-05-31
PL3157915T3 (pl) 2019-07-31
TN2016000529A1 (en) 2018-04-04
NZ726108A (en) 2020-06-26
EP3157915B1 (en) 2019-02-27
US20160376254A1 (en) 2016-12-29
TWI561516B (en) 2016-12-11
MD4820C1 (ro) 2023-03-31
CU24408B1 (es) 2019-05-03
MA40225A (fr) 2019-02-27
BR112016029612A2 (pt) 2017-08-22
MA40225B1 (fr) 2019-05-31
CR20160574A (es) 2017-02-23
PH12016502378A1 (en) 2017-02-20
AP2016009605A0 (en) 2016-12-31
CN107207464A (zh) 2017-09-26
AU2015275826A1 (en) 2016-11-24
CU20160180A7 (es) 2017-03-03
MD4820B1 (ro) 2022-08-31
EA201692114A1 (ru) 2017-06-30
US20150361067A1 (en) 2015-12-17
UY36170A (es) 2016-01-29
PE20161552A1 (es) 2017-01-11
EP3157915A1 (en) 2017-04-26
HUE042964T2 (hu) 2019-07-29
US9481666B2 (en) 2016-11-01
JP6152495B1 (ja) 2017-06-21
CL2016003246A1 (es) 2017-07-14
US20170298048A1 (en) 2017-10-19
SI3157915T1 (sl) 2019-05-31
SG11201609386YA (en) 2017-01-27
GEP20186933B (en) 2018-12-10
IL248991B (en) 2020-02-27
CA2894298C (en) 2017-04-18
CR20200484A (es) 2021-04-26
TW201609697A (zh) 2016-03-16
SV2016005333A (es) 2017-03-06
ES2721031T3 (es) 2019-07-26
DK3157915T3 (en) 2019-04-23
KR101877187B1 (ko) 2018-07-10

Similar Documents

Publication Publication Date Title
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
TN2015000281A1 (fr) Lactames condenses aryliques et heteroaryliques
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
PH12018500061A1 (en) Oxysterols and methods of use thereof
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MX2021002220A (es) Forma cristalina de base libre de lorlatinib.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12017500089A1 (en) Aldosterone synthase inhibitors
PH12016501997A1 (en) Cycloalkyl-linked diheterocycle derivatives
PH12015500399A1 (en) Azaindolines
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MY179141A (en) Dipicolylamine derivatives and their pharmaceutical uses
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs